GFAP and Alzheimer disease: Here we report a novel POC sensing platform using reduced graphene oxide/polydopamine (rGO/PDA)‐MIP matrix for the detection of GFAP, which is an astrocytic cytoskeletal protein and a discriminative biomarker for a range of neurological diseases,[20, 21, 22, 23, 24] including traumatic brain injury, glioblastoma multiforme, multiple sclerosis, stroke, and Alzheimer's disease.[25] For healthy humans, GFAP at low concentration (30‐70 pg/mL) could be detected in CSF and plasma.